| 摘要 |
The present invention relates to a composition for predicting the reactivity of a platinum-based anticancer drug therapy in a patient with ovarian cancer, by detecting a level of methylation in a CpG region on a promoter of a leucine rich repeat containing 8 family, member B (LRRC8B) gene. The present invention further relates to a kit and a method thereof. To this end, the composition of the present invention comprises a formulation used for measuring the level of methylation in the CpG region on the promoter of the LRRC8B gene. |
